Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105624 · ClinicalTrials.gov registry record · Phase 4
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)
A Phase 4 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT01105624 is a Phase 4 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 50 participants.
The verdict
NCT01105624, a Phase 4 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops
Interventions
- DRUG azithromycin ophthalmic solution, 1%
- DRUG Visine® for Contacts®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105624
The ClinicalTrials.gov registry entry for NCT01105624 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azithromycin ophthalmic solution, 1% is the first listed.
NCT01105624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105624 about?
NCT01105624 is a clinical study titled "A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)". The primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops
What is the current status of trial NCT01105624?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2010-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01105624?
The interventions under investigation include: azithromycin ophthalmic solution, 1% (DRUG), Visine® for Contacts® (DRUG).
Who is sponsoring clinical trial NCT01105624?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.